These findings may cast light on the rare adverse cardiovascular events including myocardial infarction that have been reported with anti-CD52 therapy (alemtuzumab).78 Binding of alemtuzumab to plaque LAMs within arterial walls may trigger intramural inflammation from acute damage to these cells and depletion of CD52-hi LAM from the vessel walls, thereby increasing CAD risk. This evidence concerns the gene CD52 and coronary artery disorder.